Ma Pepeluali 10, 2025, hoʻolaha ʻo CARsgen Therapeutics ua loaʻa i ke kumuhana mua i mālama ʻia me kahi lāʻau lapaʻau allogeneic BCMA CAR-T i hoʻomohala ʻia ma ka paepae THANK-u Plus™, ka pane piha koʻikoʻi (sCR) a me ka maʻi koena liʻiliʻi (MRD) ma ka loiloi Day-28. Hoʻomohala ʻia i loko o ka hale, ʻo ka paepae THANK-u Plus™ he ʻenehana CAR-T allogeneic hou i hoʻolālā ʻia e lanakila i nā pilikia hiki ke komo i ka lāʻau lapaʻau CAR-T.
ʻO ka mea maʻi, i ʻike ʻia me ka myeloma multiple relapsed/refractory, ʻano IgA-λ (R-ISS Stage II), ua hana mua ʻia ʻekolu laina o ka hui pū ʻana me ka hoʻoili ʻana o nā cell stem hematopoietic autologous. Ma hope o ka holomua o ka maʻi ma hope o ka lāʻau lapaʻau hou loa, ua kākau inoa ʻia ka mea maʻi i ka hoʻokolohua lapaʻau. Ma hope o ka hoʻokomo ʻia ʻana o nā cell CAR T ma ka pae haʻahaʻa loa e like me ke kaʻina hana lapaʻau, ua ʻike ka mea maʻi i ka Grade 1 cytokine release syndrome (CRS), kahi i mālama pono ʻia me nā antipyretics a me tocilizumab, a ʻaʻole i hōʻike ka mea maʻi i ka immune effector cell-associated neurotoxicity syndrome (ICANS) a i ʻole nā hanana ʻino ʻē aʻe e pili ana i ka CAR-T, e hōʻike ana i kahi ʻano palekana maikaʻi loa.
Ua hoʻomohala ʻia kēia lāʻau lapaʻau CAR-T no ka mālama ʻana i ka myeloma multiple relapsed/refractory (R/R MM) a me ka leukemia cell plasma relapsed/refractory (R/R PCL). Manaʻo ʻia nā mea hou aʻe e loaʻa i ka hapa lua o kēia makahiki.
I kēia manawa, nui nā hoʻokolohua lapaʻau o nā ʻenehana anti-cancer hou ma Kina e ʻimi nei i nā maʻi. I ke kūkākūkā ʻana i nā lāʻau lapaʻau a me nā ʻenehana hou, hiki iā ʻoe ke hoʻokaʻaʻike aku i ka Beijing South Region Oncology Hospital International Department.
Helu Kelepona：4008803716
Email：myimmnet@163.com
Nā Kuhikuhi
2.https://www.prnasia.com/
Ka manawa hoʻouna: Pepeluali-11-2025